NASDAQ:ARWR

Arrowhead Research Stock News

etoro logo Buy ARWR
*Your capital is at risk
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Arrowhead Pharmaceuticals and Marcus Mall MD host a webinar on ARO-ENaC for the treatment of cystic fibrosis
BidaskClub downgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a buy rating to a hold rating in a research note published on Friday morning, BidAskClub reports. A number of other researc

Stocks To Watch: Big Focus On Big Tech

08:26am, Saturday, 25'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Arrowhead reports inducement grants
Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...
Shares have more than tripled since my initial recommendation. Any dips in 2H 2020 present readers with a buying opportunity into near- and medium-term catalysts.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
Louisiana State Employees Retirement System increased its holdings in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 5.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 25,4
Advisor Group Holdings Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) during the first quarter, according to its most recent filing with the Securities & Exchange C
Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Bi
Technically speaking, the U.S. benchmarks have registered a mid-July market whipsaw, writes Michael Ashbaugh, pressured at least briefly amid the month’s...
If you want to know who really controls Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), then you'll have to look at the...
Arrowhead Pharma will host a KOL webinar on ARO-ENaC for treatment of cystic fibrosis
Arrowhead Pharma will report earnings on August 5, 2020
The RNAi treatment developer is clawing its way back after a rough start to 2020.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE